ProLung Announces Fully Subscribed Private Placement of $3.3 Million

ProLung Announces Fully Subscribed Private Placement of $3.3 Million Salt Lake City, UT, May 22, 2020 – ProLung, Inc. (“ProLung” or the “Company”), which has developed a cutting-edge predictive analytic that utilizes bioconductance to reduce the time to cancer diagnosis, announced today that its private placement of convertible notes with gross proceeds of approximately US$3.3 [...]

ProLung Announces Fully Subscribed Private Placement of $3.3 Million2020-05-22T15:04:21-06:00

ProLung Test is honored as “Most Innovative Non-Invasive Lung Cancer Testing Solution 2020” by Global Health & Pharma

ProLung Test is honored as “Most Innovative Non-Invasive Lung Cancer Testing Solution 2020” by Global Health & Pharma ProLung has been awarded the “Most Innovative Non-Invasive Lung Cancer Testing Solution 2020” by Global Health & Pharma (GHP). Jared Bauer, ProLung CEO, commented, “I am incredibly proud of our team’s accomplishments over the past 18 months, [...]

ProLung Test is honored as “Most Innovative Non-Invasive Lung Cancer Testing Solution 2020” by Global Health & Pharma2020-04-20T14:40:45-06:00

In Their Words: Jared Bauer

In Their Words: Jared Bauer Utah has an incredibly strong life sciences community with a rich history of life-saving innovation. Jared Bauer, ProLung CEO, was featured by the Utah Governor’s Office of Economic Development (GOED) last month. In the interview, you can learn more about Jared’s background and business philosophies. We are proud to have [...]

In Their Words: Jared Bauer2020-04-01T14:55:34-06:00

ProLung Test Granted ‘Breakthrough Device’ Designation by the FDA

ProLung Test Granted ‘Breakthrough Device’ Designation by the FDA Salt Lake City, UT, February 13, 2020 – ProLung, Inc. (“ProLung” or the “Company”), which has developed a cutting edge predictive analytic that utilizes bioconductance to reduce the time to cancer diagnosis, announced that its ProLung Test™ has been designated a‘Breakthrough Device’ by the U.S. Food [...]

ProLung Test Granted ‘Breakthrough Device’ Designation by the FDA2020-02-17T14:34:37-07:00

ProLung Announces End of 2012-2014 Governance Issues

ProLung Announces End of 2012-2014 Governance Issues Salt Lake City, UT, February 13, 2020 – ProLung, Inc. (“ProLung” or the “Company”), which has developed a cutting edge predictive cancer analytic that utilizes bioconductance to reduce the time to diagnosis, announced that the Utah Division of Securities (“Division”) has dismissed all charges of securities fraud against [...]

ProLung Announces End of 2012-2014 Governance Issues2020-02-17T14:34:38-07:00

CEO Today Magazine Honors ProLung CEO Jared Bauer for Leadership and Strategic Vision in 2019

CEO Today Magazine Honors ProLung CEO Jared Bauer for Leadership and Strategic Vision in 2019 We are delighted to share that Jared Bauer, ProLung CEO, has been honored for his leadership and strategic vision in 2019 by CEO Today Magazine. Jared is one of just 98 CEOs recognized nationally with this prestigious award. Every year, [...]

CEO Today Magazine Honors ProLung CEO Jared Bauer for Leadership and Strategic Vision in 20192020-02-17T14:34:38-07:00

ProLung Announces Change to its Board of Directors

ProLung Announces Change to its Board of Directors Salt Lake City, UT, November 26, 2019 – ProLung, Inc. (“ProLung” or the “Company”), which is focused on reducing the time to diagnosis for lung cancer patients, announced that Robert W. Raybould has stepped down from the Board after approximately eight years of valuable service to the [...]

ProLung Announces Change to its Board of Directors2020-02-17T14:34:38-07:00

ProLung, Inc. presents highest combined sensitivity and specificity values for a truly non-invasive lung cancer solution pursuing FDA clearance at ISRD & ATS joint medical conference

ProLung, Inc. presents highest combined sensitivity and specificity values for a truly non-invasive lung cancer solution pursuing FDA clearance at ISRD & ATS joint medical conference Salt Lake City, UT, October 31, 2019 (updated April 15, 2020) – ProLung, Inc. (“ProLung” or the “Company”) and its long-time partner ProLung China (a Delaware, USA-based company), both [...]

ProLung, Inc. presents highest combined sensitivity and specificity values for a truly non-invasive lung cancer solution pursuing FDA clearance at ISRD & ATS joint medical conference2020-04-15T10:56:37-06:00

ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 74% specificity

ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 73% specificity Salt Lake City, UT, October 3, 2019 (updated April 15, 2020) – ProLung, Inc. (“ProLung” or the “Company”) and its long-time partner ProLung China (a Delaware, USA-based company), both whom are focused on reducing the time to diagnosis for lung cancer patients, [...]

ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 74% specificity2020-04-15T10:57:18-06:00

ProLung Promotes Jared Bauer from interim CEO to CEO

ProLung Promotes Jared Bauer from interim CEO to CEO Salt Lake City, UT, October 2, 2019 – ProLung, Inc. (“ProLung” or the “Company”), which is focused on reducing the time to diagnosis for lung cancer patients, announced today the promotion of Mr. Jared Bauer from interim CEO to CEO. Mr. Bauer joined ProLung in July [...]

ProLung Promotes Jared Bauer from interim CEO to CEO2020-02-17T14:34:38-07:00